Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer's pathology

G. Mittal, H. Carswell, R. Brett, S. Currie, M. N. V. Ravi Kumar

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

The purpose of this study was to develop tween 80 (T-80) coated polylactide-co-glycolide (PLGA) nanoparticles that can deliver estradiol to the brain upon oral administration. Estradiol containing nanoparticles were made by a single emulsion technique and T-80 coating was achieved by incubating the re-constituted nanoparticles at different concentrations of T-80. The process of T-80 coating on the nanoparticles was optimized and the pharmacokinetics of estradiol nanoparticles was studied as a function of T-80 coating. The nanoparticles were then evaluated in an ovariectomized (OVX) rat model of Alzheimer's disease (AD) that mimics the postmenopausal conditions. The nanoparticles bound T-80 were found to proportionally increase from 9.72 +/- 1.07 mg to 63.84 +/- 3.59 mg with an increase in the initial concentration T-80 from 1% to 5% and were stable in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF). Orally administered T-80 coated nanoparticles resulted in significantly higher brain estradiol levels after 24 h (1.969 +/- 0.197 ng/g tissue) as compared to uncoated ones (1.105 +/- 0.136 ng/g tissue) at a dose of 0.2 mg/rat suggesting a significant role of surface coating. Moreover, these brain estradiol levels were almost similar to those obtained after administration of the same dose of drug suspension via 100% bioavailable intramuscular route (2.123 +/- 0.370 ng/g tissue), indicating the increased fraction of bioavailable drug reaching the brain when administered orally. Also, the nanoparticle treated group was successful in preventing the expression of amyloid beta-42 (A beta 42) immunoreactivity in the hippocampus region of brain. Together, the results indicate the potential of nanoparticles for oral delivery of estradiol to brain. (C) 2010 Elsevier B.V. All rights reserved.

LanguageEnglish
Pages220-228
Number of pages9
JournalJournal of Controlled Release
Volume150
Issue number2
DOIs
Publication statusPublished - 10 Mar 2011

Fingerprint

Nanoparticles
Estradiol
Polymers
Pathology
Brain
Polysorbates
Emulsions
Amyloid
Pharmaceutical Preparations
Oral Administration
Hippocampus
Stomach
Suspensions
Alzheimer Disease
Pharmacokinetics

Keywords

  • amyloid beta
  • biodegradable
  • brain targeting
  • nanoparticles
  • oxidative stress
  • oral delivery
  • elevated plus-maze
  • D-Galactose
  • disease
  • BETA
  • astrocytes
  • dalargin
  • therapy
  • biodistribution
  • accumulation
  • efficacy

Cite this

@article{6ba20c1d626a4d98a005fef3c598ef07,
title = "Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer's pathology",
abstract = "The purpose of this study was to develop tween 80 (T-80) coated polylactide-co-glycolide (PLGA) nanoparticles that can deliver estradiol to the brain upon oral administration. Estradiol containing nanoparticles were made by a single emulsion technique and T-80 coating was achieved by incubating the re-constituted nanoparticles at different concentrations of T-80. The process of T-80 coating on the nanoparticles was optimized and the pharmacokinetics of estradiol nanoparticles was studied as a function of T-80 coating. The nanoparticles were then evaluated in an ovariectomized (OVX) rat model of Alzheimer's disease (AD) that mimics the postmenopausal conditions. The nanoparticles bound T-80 were found to proportionally increase from 9.72 +/- 1.07 mg to 63.84 +/- 3.59 mg with an increase in the initial concentration T-80 from 1{\%} to 5{\%} and were stable in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF). Orally administered T-80 coated nanoparticles resulted in significantly higher brain estradiol levels after 24 h (1.969 +/- 0.197 ng/g tissue) as compared to uncoated ones (1.105 +/- 0.136 ng/g tissue) at a dose of 0.2 mg/rat suggesting a significant role of surface coating. Moreover, these brain estradiol levels were almost similar to those obtained after administration of the same dose of drug suspension via 100{\%} bioavailable intramuscular route (2.123 +/- 0.370 ng/g tissue), indicating the increased fraction of bioavailable drug reaching the brain when administered orally. Also, the nanoparticle treated group was successful in preventing the expression of amyloid beta-42 (A beta 42) immunoreactivity in the hippocampus region of brain. Together, the results indicate the potential of nanoparticles for oral delivery of estradiol to brain. (C) 2010 Elsevier B.V. All rights reserved.",
keywords = "amyloid beta, biodegradable, brain targeting, nanoparticles, oxidative stress, oral delivery, elevated plus-maze, D-Galactose, disease, BETA, astrocytes, dalargin, therapy, biodistribution, accumulation, efficacy",
author = "G. Mittal and H. Carswell and R. Brett and S. Currie and Kumar, {M. N. V. Ravi}",
year = "2011",
month = "3",
day = "10",
doi = "10.1016/j.jconrel.2010.11.013",
language = "English",
volume = "150",
pages = "220--228",
journal = "Journal of Controlled Release",
issn = "0168-3659",
number = "2",

}

Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer's pathology. / Mittal, G.; Carswell, H.; Brett, R.; Currie, S.; Kumar, M. N. V. Ravi.

In: Journal of Controlled Release, Vol. 150, No. 2, 10.03.2011, p. 220-228.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer's pathology

AU - Mittal, G.

AU - Carswell, H.

AU - Brett, R.

AU - Currie, S.

AU - Kumar, M. N. V. Ravi

PY - 2011/3/10

Y1 - 2011/3/10

N2 - The purpose of this study was to develop tween 80 (T-80) coated polylactide-co-glycolide (PLGA) nanoparticles that can deliver estradiol to the brain upon oral administration. Estradiol containing nanoparticles were made by a single emulsion technique and T-80 coating was achieved by incubating the re-constituted nanoparticles at different concentrations of T-80. The process of T-80 coating on the nanoparticles was optimized and the pharmacokinetics of estradiol nanoparticles was studied as a function of T-80 coating. The nanoparticles were then evaluated in an ovariectomized (OVX) rat model of Alzheimer's disease (AD) that mimics the postmenopausal conditions. The nanoparticles bound T-80 were found to proportionally increase from 9.72 +/- 1.07 mg to 63.84 +/- 3.59 mg with an increase in the initial concentration T-80 from 1% to 5% and were stable in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF). Orally administered T-80 coated nanoparticles resulted in significantly higher brain estradiol levels after 24 h (1.969 +/- 0.197 ng/g tissue) as compared to uncoated ones (1.105 +/- 0.136 ng/g tissue) at a dose of 0.2 mg/rat suggesting a significant role of surface coating. Moreover, these brain estradiol levels were almost similar to those obtained after administration of the same dose of drug suspension via 100% bioavailable intramuscular route (2.123 +/- 0.370 ng/g tissue), indicating the increased fraction of bioavailable drug reaching the brain when administered orally. Also, the nanoparticle treated group was successful in preventing the expression of amyloid beta-42 (A beta 42) immunoreactivity in the hippocampus region of brain. Together, the results indicate the potential of nanoparticles for oral delivery of estradiol to brain. (C) 2010 Elsevier B.V. All rights reserved.

AB - The purpose of this study was to develop tween 80 (T-80) coated polylactide-co-glycolide (PLGA) nanoparticles that can deliver estradiol to the brain upon oral administration. Estradiol containing nanoparticles were made by a single emulsion technique and T-80 coating was achieved by incubating the re-constituted nanoparticles at different concentrations of T-80. The process of T-80 coating on the nanoparticles was optimized and the pharmacokinetics of estradiol nanoparticles was studied as a function of T-80 coating. The nanoparticles were then evaluated in an ovariectomized (OVX) rat model of Alzheimer's disease (AD) that mimics the postmenopausal conditions. The nanoparticles bound T-80 were found to proportionally increase from 9.72 +/- 1.07 mg to 63.84 +/- 3.59 mg with an increase in the initial concentration T-80 from 1% to 5% and were stable in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF). Orally administered T-80 coated nanoparticles resulted in significantly higher brain estradiol levels after 24 h (1.969 +/- 0.197 ng/g tissue) as compared to uncoated ones (1.105 +/- 0.136 ng/g tissue) at a dose of 0.2 mg/rat suggesting a significant role of surface coating. Moreover, these brain estradiol levels were almost similar to those obtained after administration of the same dose of drug suspension via 100% bioavailable intramuscular route (2.123 +/- 0.370 ng/g tissue), indicating the increased fraction of bioavailable drug reaching the brain when administered orally. Also, the nanoparticle treated group was successful in preventing the expression of amyloid beta-42 (A beta 42) immunoreactivity in the hippocampus region of brain. Together, the results indicate the potential of nanoparticles for oral delivery of estradiol to brain. (C) 2010 Elsevier B.V. All rights reserved.

KW - amyloid beta

KW - biodegradable

KW - brain targeting

KW - nanoparticles

KW - oxidative stress

KW - oral delivery

KW - elevated plus-maze

KW - D-Galactose

KW - disease

KW - BETA

KW - astrocytes

KW - dalargin

KW - therapy

KW - biodistribution

KW - accumulation

KW - efficacy

U2 - 10.1016/j.jconrel.2010.11.013

DO - 10.1016/j.jconrel.2010.11.013

M3 - Article

VL - 150

SP - 220

EP - 228

JO - Journal of Controlled Release

T2 - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 2

ER -